Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine which of these anti-clotting medications, abciximab
plus unfractionated heparin or bivalirudin, is more effective to prevent thrombotic and
bleeding complications in patients suffering from a heart attack and undergoing coronary
intervention.